News
Syndax Pharmaceuticals Announced The Presentation Of Data From AUGMENT-101 Trial In Pediatric Patients With Relapsed/Refractory KMT2A-rearranged Acute Myeloid Leukemia And Acute Lymphoid Leukemia Treated With Revumenib
8 Apr 24
Biotech, News, Health Care, General
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
28 Mar 24
News, Price Target, Reiteration, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
27 Mar 24
News, Price Target, Analyst Ratings
Syndax Reports FDA Priority Review Of NDA For Revumenib For Treatment Of Relapsed/Refractory KMT2Ar Acute Leukemia
26 Mar 24
Biotech, News, FDA, General
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $34
20 Mar 24
News, Price Target, Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
28 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Syndax Pharmaceuticals Expects $600M In Cash And Equivalents To Provide Runway Through 2026;
27 Feb 24
News, Guidance
Syndax Pharmaceuticals: Q4 Earnings Insights
27 Feb 24
Earnings
Syndax Pharmaceuticals Q4 2023 GAAP EPS $(1.00) Misses $(0.99) Estimate
27 Feb 24
Earnings, Earnings Misses, News
Earnings Scheduled For February 27, 2024
27 Feb 24
Earnings
Earnings Preview: Syndax Pharmaceuticals
26 Feb 24
Earnings
Scotiabank Downgrades Syndax Pharmaceuticals to Sector Perform, Lowers Price Target to $23
31 Jan 24
News, Downgrades, Price Target, Analyst Ratings
Press releases
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
10 Apr 24
Press Releases
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
8 Apr 24
Press Releases
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5 Apr 24
Press Releases
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
28 Mar 24
Press Releases
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
28 Mar 24
News, Management, Press Releases
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
26 Mar 24
Press Releases
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1 Mar 24
Press Releases
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
27 Feb 24
Press Releases
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
27 Feb 24
Earnings, Press Releases
Syndax Announces Participation at Two Upcoming Investor Conferences
26 Feb 24
Press Releases
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2 Feb 24
Press Releases
Syndax Announces Participation at Two Upcoming Investor Conferences
1 Feb 24
Press Releases